---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-308899"
form_type: "8-K"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2026-07-20T20:00:14+00:00"
generated_at: "2026-07-20T20:01:59.969130+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Damora Therapeutics completes redomestication from Delaware to Cayman Islands

## Summary
- Redomestication effective July 16, 2026; each common share converted 1:1 into ordinary shares of Cayman company.
- New CUSIP G2646Y104; ordinary shares continue trading on Nasdaq under symbol DMRA as of July 20, 2026.
- No change in business, management, obligations, assets, or liabilities; company remains a U.S. corporation for tax purposes.
- Stockholders approved the redomestication at a special meeting on February 9, 2026.
- Company also entered into indemnification agreements with directors and executive officers.

## SEC filing metadata
- accession: 0001193125-26-308899
- form_type: 8-K
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2026-07-20T20:00:14+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/0001193125-26-308899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/dmra-20260716.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-308899
- JSON: https://secwatch.observer/filing/0001193125-26-308899.json
- Plain text: https://secwatch.observer/filing/0001193125-26-308899.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.